Please select the option that best describes you:
Would you give adjuvant immunotherapy after nephrectomy?
Is DFS benefit in KN-564 in ASCO2021 sufficient evidence to change practice?
Answer from: Medical Oncologist at Academic Institution
The KN-564 will certainly change the landscape of adjuvant RCC. Prior studies had either been negative, or have been positive (sunitinib in S-TRAC) but with toxicity that has precluded widespread use. The OS data from KN-564 is too immature to interpret, in my opinion, so the debate of whether to tr...
Sign in or Register to read more